Volume 3 | Issue 3 | DOI: https://doi.org/10.33696/diabetes.3.044
Commentary on Once-Weekly Semaglutide in Adults with Overweight or Obesity
- 1Division of Diabetes, Endocrinology & Metabolism, Department of Medicine, Vanderbilt University School of Medicine, Nashville,TN, USA
- 2Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA
- 3Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, TN, USA
Gitanjali Srivastava, email@example.com
Received Date: August 19, 2021
Accepted Date: August 24, 2021
Garner EM, Niswender KD, Srivastava G. Commentary on Once-Weekly Semaglutide in Adults with Overweight or Obesity. J Diabetes Clin Res. 2021; 3(3):81-84.
Copyright: © 2021 Garner EM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
GLP-1R agonist, Semaglutide, Overweight, Obesity, Weight loss, Diabetes, Anti-obesity medication
However, the entire coagulation cascade is dysfunctional, in progressed chronic diabetes and cancer patients.
How Traditional Healers Diagnose and Treat Diabetes Mellitus in the Pretoria Mamelodi Area and How Do These Purported Medications Comply with Complementary and Alternative Medicine Regulations
CAM is widely used by patients to treat and prevent certain diseases, providing emotional and physical support . The National Centre for Complementary and Alternative Medicine (NCCAM) defines CAM as a “group of diverse medical and health care systems, practices, and products that are not presently considered to be part of conventional medicine” .
Worldwide, obesity is a public health concern and a metabolic ailment characterized by excessive adipose tissue accumulation resulting from an imbalance of energy expenditure and energy intake . This disorder is a known risk factor for cardiovascular disease, type 2 diabetes mellitus, dyslipidemia, hypertension, and metabolic
Obesity has reached a global epidemic and it predisposes to the development of insulin resistance, type 2 diabetes and related metabolic diseases. Current interventions against obesity and/or type 2 diabetes such as calorie restriction, exercise, genetic manipulations or established pharmacological treatments have not been successful for many patients with obesity and/or type 2 diabetes.
Prevalence of diabetes is increasing. Diabetes is more prevalent in the socially deprived, ethnic minority population (based on continuing rise in elderly population, growing obesity and BME groups). Compliance is a major stumbling block in the management of most long-term conditions including diabetes.